Alkermes plc.

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. It also maintains a pipeline of clinical and preclinical candidates for neurological disorders. Alkermes is headquartered in Ireland, with a corporate office and R&D center in Massachusetts, and a manufacturing facility in Ohio. On February 12, 2026, Alkermes completed the acquisition of Avadel Pharmaceuticals plc, adding LUMRYZ to its proprietary commercial products and gaining a commercial organization experienced in narcolepsy. The acquisition involved consideration of $21.00 per Avadel ordinary share in cash at closing, plus a non-transferable contingent value right for a potential additional cash payment of $1.50 per Avadel share upon achieving a specified milestone. Alkermes' proprietary commercial products include treatments for schizophrenia, narcolepsy, bipolar I disorder, alcohol dependence, and opioid dependence in the U.S. Additionally, the company licenses its proprietary technologies for key third-party products. For example, RISPERDAL CONSTA, indicated for schizophrenia and bipolar I disorder, is commercialized by Janssen Pharmaceuticals, Inc. in a licensed territory.